UNSPSC 51201523: Anakinra

This classification denotes an interleukin-1 receptor antagonist with the molecular formula C759H1186N208O232S10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9013DUQ28K, more generally known as anakinra. European Medicines Agency schedules anakinra in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05500MIG. The term ANAKINRA is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 9, no. 3, 1995, list 35.

ANAKINRA is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule anakinra under HS 30021095 and SITC 54163. As of Q4 2014, ANAKINRA remains the US FDA Preferred Term for this commodity. Anakinra bears US NLM identifiers UMLS ID C0245109 and NCI Concept Code C38717. SMILES: none.

UNSPSC 51201523 Anakinra is a Commodity-tier code for a specific biopharmaceutical product used to treat inflammatory and autoinflammatory conditions. Recent state and local procurement activity under this code does not reflect purchases of anakinra itself; instead, the tagged opportunities show a significant scope mismatch. The City of Tucson's RFP for athletic training services (posted May 13, 2026, due June 9, 2026) requests injury prevention, rehabilitation, and fitness programs for fire and police departments — work entirely unrelated to pharmaceutical procurement. The City of Tampa's ITB for medical aid supplies (posted April 24, 2026) covers first-aid items such as bandages, aspirin, and antiseptic sprays rather than biopharmaceuticals. The Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescriptions (posted April 3, 2026) addresses pharmacy benefit management and contracting models but does not reference anakinra or any specific pharmaceutical products. The code shows little relevant recent activity among state and local buyers; the opportunities posted do not align with anakinra procurement or injectable biologic therapies more broadly.

No recent state and local contract opportunities soliciting anakinra or related biopharmaceutical therapies appear in the dataset. The mismatch between the code's nominal scope and the actual work being tagged suggests either a data-classification error or minimal state and local demand for this specific drug product. Buyers seeking anakinra typically operate through pharmacy benefit managers, group purchasing organizations, or existing health plan contracts rather than standalone solicitations, and state and local entities may source it through cooperative purchasing vehicles or existing statewide agreements not captured in this activity feed.